Optimizing HEK293 media for improved titers and VG/Capsid ratios
Sponsor
Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy.
The manufacturing of viral vectors for gene therapy can be a challenging process. Due to the complexity of their production and purification, viral vectors can be very expensive to produce.
To help cell and gene therapy product manufacturers discover the optimal HEK293 media for their viral vector-based applications, FUJIFILM Irvine Scientific has developed the HEK293 Media Survey Panel (HSMP).
The HMSP is a curated panel of six growth media and three feed supplements of high-quality, scalable, CD HEK media. Designed to improve growth and production of AAV and AAV2 serotypes, the HSMP optimizes HEK293 media allowing for increased titers and improved VG/Capsid ratios. Choosing the proper media in a scale-down model for each cell line and process can improve yield and lower production costs as well as managing to the demand for high demand and dosage of the therapeutics.
Learn more about the HEK293 Media Survey panel and discover your optimal media, and streamline the workflow process for viral vector production while increasing transfection efficacy and cell growth consistency.
- Optimize your HEK293 media for cell and gene therapy, and viral vector-based vaccine applications
- Discover how HMSP growth media can significantly improve growth and production of AAV and AAV2 serotypes
- The advantage of choosing the proper scale-down model for each cell line to improve yield and lower production costs
- Evaluate/Determine/Explore the optimal media for increased titers and VG/capsid ratios for therapeutic development.
- Streamline the workflow process for viral vector production while increasing transfection efficacy and cell growth consistency.
SPEAKERS